Infinity Reports Phase 1 Data for IPI-145 at ACR/ARHP Supporting Development in Inflammatory Conditions

Infinity Pharmaceuticals (NASDAQ: INFI) today announced new data fromits completed Phase 1 study of IPI-145, the company's potent, oral inhibitorof phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data showed thatIPI-145 was well tolerated and demonstrated favorable pharmacokineticsfollowing administration of single and multiple doses in healthy adultsubjects. Infinity also presented data demonstrating the activity of IPI-145in preclinical models of rheumatoid arthritis (RA). These findings werepresented at the American College of Rheumatology (ACR)/Association ofRheumatology Health Professionals (ARHP) 2012 Annual Meeting held inWashington, DC.“These data show that IPI-145 is well tolerated in healthy subjects andinhibits immune cell activation even at low doses,” stated Vito J. Palombella,chief scientific officer at Infinity. “The profile of IPI-145 observed in thisPhase 1 trial, combined with our preclinical studies in inflammation, supportPhase 2 clinical development in patients with asthma and RA as well as otherpotential inflammatory indications.”The PI3Ks are a family of enzymes involved in multiple cellular functions,such as cell proliferation and survival, metabolism, cell differentiation andcellular trafficking.^1 PI3K-delta and -gamma, two isoforms of PI3K, arenecessary for adaptive and innate immunity, and the role of these enzymes invarious immune cells supports the development of IPI-145 for the treatment ofinflammatory disorders as well as hematologic malignancies.^2 Infinitybelieves that IPI-145 is the only PI3K-delta and -gamma inhibitor currently inclinical development.